Vitro Diagnostics Inc. (fka VODG)

[Potse]

JonesBur...VODG's SEC requirements.....

Question- do they have to file a 10Q being on the OTC? Or can they just skip a quarter and move on to the next one with no negative consequences? I think the answer is no they don't have to file, but not sure of any negative consequences?

I don't know what is occurring at Vitro Biopharma, but presumably one of the following is the most likely scenario....

1) VODG intends to voluntarily suspend its SEC filing obligations
2) VODG is having acquisition/merger discussions, and intends to complete a transaction in the relatively near future
3) Some behind-the-scenes situation has caused the company to become temporarily deliquent in its SEC filings

If the company is planning to voluntarily suspend its SEC filing obligations (by filing a 15-12G), it "technically/legally" will need to become current with its SEC filings before making that 15-12G filing application. So VODG would "technically/legally" need to file both its February-April Q2 (which is deliquent) and its May-July Q3 report.

Some companies never get all the required periodic filings completed and just file the 15-12G, however this does place the stock at additional/unneccessary risk of having the SEC eventually suspend the stock and revoke its registration. Until there are significant changes in management/personnel at the SEC (and an accompanying change in attitude toward smaller companies, shells, reverse mergers, etc), companies need to do everything they can to limit their suspension/revocation risk.

A 15-12G filing can only be made if there is less than 300 shareholders in the stock. So if VODG is planning to file a 15-12G, it would more than likely need to implement a reverse split, cashout, and forward split procedure in order to get the shareholder count under the required level.